E
Envisagenics
Biotech & Life Sciences · New York City, United States · Founded 2014
Leveraging artificial intelligence, high performance computing, and RNA sequencing data to find cures faster than ever before MoreLess
An AI-driven biotechnology company focused on RNA splicing therapeutics. Its proprietary SpliceCore® platform uses cloud-based, machine learning algorithms to analyze RNA data, identifying new drug targets and biomarkers.
Envisagenics's primary clients are pharmaceutical and biotechnology companies. The company's business model revolves around its SpliceCore platform, which it uses to form strategic partnerships to accelerate the discovery and development of new therapies. It also has an internal pipeline of drug candidates in oncology and neurodegenerative diseases.
Keywords: RNA splicing, drug discovery, artificial intelligence, biotechnology, therapeutics, SpliceCore, oncology, neurodegeneration, machine learning, biomarkers
Company overview
Envisagenics company information
The essential company record, classifications and operating signals in one place.
- Status
- Operational
- Founded
- 2014
- Headquarters
- New York City, United States
- Employees
- 37
- Open positions
- None listed
- Dealroom signal
- 61.8
Valuation & funding
Envisagenics funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SERIES B✓Equity / VC | Jun 2024 | $25M | $100M | Empire State Development · Bristol-Myers Squibb · Third Kind Venture Capital · Red Cell Partners | ↗ |
| SERIES AEquity / VC | May 2023 | $0 | — | Undisclosed | — |
| GRANT✓Other financing | Aug 2022 | $2M | — | Dynamk Capital · Topspin Communications · National Cancer Institute (NCI) · M12 | ↗ |
| GRANT✓Other financing | Jan 2022 | $1M | — | Small Business Innovation Research | — |
| SERIES A✓Equity / VC | Sep 2021 | — | — | Madrona Venture Group · Red Cell Partners · New York Ventures · Dynamk Capital | — |
| SERIES AEquity / VC | Sep 2020 | Undisclosed | — | ||
| GRANTOther financing | Sep 2019 | National Institutes of Health | — | ||
| GRANT✓Other financing | Jan 2019 | Small Business Innovation Research | — | ||
| GRANT✓Other financing | May 2018 | National Institutes of Health | — | ||
| SEED✓Equity / VC | Nov 2017 | SV Angel · Empire State Development · Third Kind Venture Capital · Dynamk Capital | ↗ |
Financials
Workforce over time
Available workforce history. Financial fields without reported data are omitted.
| Year | Employees |
|---|---|
| 2026 | 35 |
| 2025 | 42 |
| 2024 | 49 |
| 2023 | 42 |
| 2022 | 34 |
| 2021 | 25 |
Growth signals
Envisagenics website traffic
Latest recorded traffic for Envisagenics is 1.5K monthly website visits, up 25% over the last three months. Envisagenics's team declined 11.9% over the past year.
Comparisons
Envisagenics compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Envisagenics's talent
Source: Dealroom Talent Intelligence.
Global footprint
Where Envisagenics has talent and traffic
team presence
In the news
Latest news about Envisagenics
Recent press, funding announcements, and product moves mentioning Envisagenics — open to read from the original sources.
Market sentiment
What the market is saying about Envisagenics
An AI-synthesized read of the highest-engagement posts about Envisagenics on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Envisagenics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.